Answers are grounded in this paper and cite their sources.
Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
No takes yet. Share an insight, caveat, or question.
Salloway et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: